PAUL J HASTINGS Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for PAUL J HASTINGS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of PAUL J HASTINGS. PAUL J HASTINGS is President & CEO in QLT INC/BC ($QLTI) and Chairman & CEO in OncoMed Pharmaceuticals Inc ($OMED) and Chief Executive Officer in OncoMed Pharmaceuticals Inc ($OMED) and Director in PROTEON THERAPEUTICS INC ($PRTO) and Director in Pacira Pharmaceuticals, Inc. ($PCRX) and Director in Relypsa Inc ($RLYP) and Chief Executive Officer in Nkarta, Inc. ($NKTX) and See Remarks in Nkarta, Inc. ($NKTX).
Latest Insider Trading Transactions of PAUL J HASTINGS
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, NKTX, NVLN, OMED, PCRX, TARA, RLYP
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11 2021 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Option Exercise | A | 60.96 | 7,626 | 464,881 | 7,626 | |
| Jun 11 2021 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 1,066 | 0 | 6,552 | 5.5 K to 6.6 K (+19.43 %) |
| Apr 01 2021 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | Chief Executive Off ... | Sell | S | 32.21 | 3,130 | 100,817 | 236,061 | 239.2 K to 236.1 K (-1.31 %) |
| Apr 01 2021 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | Chief Executive Off ... | Sell | S | 31.24 | 2,409 | 75,257 | 239,191 | 241.6 K to 239.2 K (-1.00 %) |
| Apr 01 2021 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | Chief Executive Off ... | Sell | S | 30.23 | 11,461 | 346,466 | 241,600 | 253.1 K to 241.6 K (-4.53 %) |
| Mar 09 2021 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Option Exercise | M | 13.98 | 3,000 | 41,940 | 0 | |
| Mar 09 2021 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Sell | S | 65.88 | 3,000 | 197,640 | 6,116 | 9.1 K to 6.1 K (-32.91 %) |
| Mar 09 2021 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Buy | M | 13.98 | 3,000 | 41,940 | 9,116 | 6.1 K to 9.1 K (+49.05 %) |
| Jan 12 2021 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | Chief Executive Off ... | Option Exercise | A | 54.89 | 157,500 | 8,645,175 | 157,500 | |
| Jul 13 2020 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | See Remarks | Option Exercise | A | 18.00 | 202,400 | 3,643,200 | 202,400 | |
| Jul 13 2020 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | See Remarks | Option Exercise | A | 18.00 | 202,400 | 3,643,200 | 202,400 | |
| Jun 11 2020 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Option Exercise | A | 47.65 | 8,027 | 382,487 | 8,027 | |
| Jun 11 2020 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 1,260 | 0 | 6,116 | 4.9 K to 6.1 K (+25.95 %) |
| Jun 08 2020 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Sell | S | 47.46 | 2,025 | 96,107 | 4,856 | 6.9 K to 4.9 K (-29.43 %) |
| Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
| Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 4,134 | 0 | 6,881 | 2.7 K to 6.9 K (+150.49 %) |
| Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Sell | S | 42.66 | 782 | 33,360 | 2,747 | 3.5 K to 2.7 K (-22.16 %) |
| Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
| Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 4,134 | 0 | 6,881 | 2.7 K to 6.9 K (+150.49 %) |
| Jun 06 2019 | PCRX | Pacira BioSciences ... | HASTINGS PAUL J | Director | Sell | S | 42.66 | 782 | 33,360 | 2,747 | 3.5 K to 2.7 K (-22.16 %) |
| Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
| Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 782 | 0 | 3,529 | 2.7 K to 3.5 K (+28.47 %) |
| Jun 11 2018 | PRTO | PROTEON THERAPEUTI ... | HASTINGS PAUL J | Director | Option Exercise | A | 2.50 | 12,700 | 31,750 | 12,700 | |
| Jun 06 2018 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Sell | S | 33.90 | 771 | 26,137 | 2,747 | 3.5 K to 2.7 K (-21.92 %) |
| Oct 12 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 4.24 | 1,346 | 5,709 | 76,188 | 77.5 K to 76.2 K (-1.74 %) |
| Oct 12 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 4.26 | 52 | 222 | 77,534 | 77.6 K to 77.5 K (-0.07 %) |
| Aug 24 2017 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Sell | S | 36.15 | 1,044 | 37,741 | 3,518 | 4.6 K to 3.5 K (-22.88 %) |
| Jun 21 2017 | PRTO | PROTEON THERAPEUTI ... | HASTINGS PAUL J | Director | Option Exercise | A | 1.30 | 6,666 | 8,666 | 6,666 | |
| Jun 16 2017 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | A | 44.20 | 2,714 | 119,959 | 2,714 | |
| Jun 16 2017 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 1,357 | 0 | 4,562 | 3.2 K to 4.6 K (+42.34 %) |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | A | 3.77 | 135,000 | 508,950 | 135,000 | |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Grant | A | 0.00 | 45,000 | 0 | 77,586 | 32.6 K to 77.6 K (+138.10 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 9.06 | 6,425 | 58,199 | 32,586 | 39 K to 32.6 K (-16.47 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 8.87 | 48 | 426 | 39,011 | 39.1 K to 39 K (-0.12 %) |
| Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | M | 1.43 | 21,369 | 30,558 | 0 | |
| Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | M | 1.43 | 21,369 | 30,558 | 21,369 | |
| Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 8.52 | 21,369 | 181,957 | 37,323 | 58.7 K to 37.3 K (-36.41 %) |
| Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Buy | M | 1.43 | 21,369 | 30,558 | 58,692 | 37.3 K to 58.7 K (+57.25 %) |
| Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 8.17 | 21,369 | 174,602 | 37,323 | 58.7 K to 37.3 K (-36.41 %) |
| Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Buy | M | 1.43 | 21,369 | 30,558 | 58,692 | 37.3 K to 58.7 K (+57.25 %) |
| Jan 05 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | A | 7.66 | 176,000 | 1,348,160 | 176,000 | |
| Oct 20 2016 | PRTO | PROTEON THERAPEUTI ... | HASTINGS PAUL J | Director | Option Exercise | A | 9.00 | 13,333 | 119,997 | 13,333 | |
| Oct 11 2016 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Grant | A | 0.00 | 14,000 | 0 | 37,323 | 23.3 K to 37.3 K (+60.03 %) |
| Sep 02 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Option Exercise | D | 17.00 | 4,500 | 76,500 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Option Exercise | D | 35.79 | 4,500 | 161,055 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Option Exercise | D | 23.96 | 3,828 | 91,719 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Option Exercise | D | 7.40 | 15,953 | 118,052 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Option Exercise | D | 3.96 | 21,802 | 86,336 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Sell | D | 32.00 | 2,250 | 72,000 | 0 | 2.3 K to 0 (-100.00 %) |
| Sep 02 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Sell | U | 32.00 | 2,495 | 79,840 | 2,250 | 4.7 K to 2.3 K (-52.58 %) |
| Jun 23 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Option Exercise | A | 17.00 | 4,500 | 76,500 | 4,500 | |
| Jun 23 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Grant | A | 0.00 | 2,250 | 0 | 4,745 | 2.5 K to 4.7 K (+90.18 %) |
| Jun 17 2016 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | A | 40.34 | 2,975 | 120,012 | 2,975 | |
| Jun 17 2016 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 1,488 | 0 | 3,205 | 1.7 K to 3.2 K (+86.66 %) |
| Jun 08 2016 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Sell | S | 46.95 | 1,136 | 53,335 | 1,717 | 2.9 K to 1.7 K (-39.82 %) |
| Jun 08 2016 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Sell | S | 19.32 | 1,013 | 19,573 | 2,495 | 3.5 K to 2.5 K (-28.88 %) |
| Feb 22 2016 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | M | 10.81 | 1,000 | 10,810 | 0 | |
| Feb 22 2016 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | M | 13.98 | 2,000 | 27,960 | 3,000 | |
| Feb 22 2016 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Sell | S | 60.00 | 3,000 | 180,000 | 2,853 | 5.9 K to 2.9 K (-51.26 %) |
| Feb 22 2016 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Buy | M | 10.81 | 1,000 | 10,810 | 5,853 | 4.9 K to 5.9 K (+20.61 %) |
| Feb 22 2016 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Buy | M | 13.98 | 2,000 | 27,960 | 4,853 | 2.9 K to 4.9 K (+70.10 %) |
| Jan 08 2016 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 21.54 | 77 | 1,659 | 22,025 | 22.1 K to 22 K (-0.35 %) |
| Jan 08 2016 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 22.30 | 2,335 | 52,072 | 22,102 | 24.4 K to 22.1 K (-9.56 %) |
| Dec 29 2015 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chief Executive Off ... | Option Exercise | A | 21.43 | 170,000 | 3,643,100 | 170,000 | |
| Nov 24 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | M | 10.81 | 3,000 | 32,430 | 1,000 | |
| Nov 24 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Sell | S | 60.00 | 3,000 | 180,000 | 2,853 | 5.9 K to 2.9 K (-51.26 %) |
| Nov 24 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Buy | M | 10.81 | 3,000 | 32,430 | 5,853 | 2.9 K to 5.9 K (+105.15 %) |
| Aug 19 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | M | 10.81 | 3,000 | 32,430 | 4,000 | |
| Aug 19 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Sell | S | 60.02 | 3,000 | 180,060 | 2,853 | 5.9 K to 2.9 K (-51.26 %) |
| Aug 19 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Buy | M | 10.81 | 3,000 | 32,430 | 5,853 | 2.9 K to 5.9 K (+105.15 %) |
| Jun 15 2015 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Sell | S | 34.63 | 1,454 | 50,359 | 3,508 | 5 K to 3.5 K (-29.30 %) |
| Jun 08 2015 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Option Exercise | A | 35.79 | 4,500 | 161,055 | 4,500 | |
| Jun 08 2015 | RLYP | Relypsa Inc | HASTINGS PAUL J | Director | Grant | A | 0.00 | 2,250 | 0 | 4,962 | 2.7 K to 5 K (+82.96 %) |
| Jun 05 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | A | 79.43 | 4,000 | 317,720 | 4,000 | |
| Jun 05 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Grant | A | 0.00 | 2,000 | 0 | 2,853 | 853 to 2.9 K (+234.47 %) |
| Apr 14 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Option Exercise | M | 13.98 | 2,500 | 34,950 | 5,000 | |
| Apr 14 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Sell | S | 88.00 | 2,500 | 220,000 | 853 | 3.4 K to 853 (-74.56 %) |
| Apr 14 2015 | PCRX | Pacira Pharmaceuti ... | HASTINGS PAUL J | Director | Buy | M | 13.98 | 2,500 | 34,950 | 3,353 | 853 to 3.4 K (+293.08 %) |
| Apr 29 2005 | QLTI | QLT INC/BC | HASTINGS PAUL J | President & CEO | Buy | P | 10.77 | 900 | 9,693 | 9,500 | 8.6 K to 9.5 K (+10.47 %) |
| Mar 10 2005 | QLTI | QLT INC/BC | HASTINGS PAUL J | President & CEO | Option Exercise | A | 12.45 | 100,000 | 1,245,000 | 100,000 |
Page: 1